Today: 11 April 2026
Subscribe
Browse Category

NYSE:PFE 3 February 2026 - 6 April 2026

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners sold a combined 740,174 Pfizer shares in the fourth quarter, according to recent 13F filings. Pfizer stock traded down 0.7% at $28.12 Monday. The three firms still held about $140.9 million in Pfizer shares at year-end. Pfizer halted a major U.S. COVID shot study after the period covered by the filings.
6 April 2026
··
Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer shares hit a 52-week high of $28.30 in New York Tuesday, lifted by recent drug pipeline updates and strong fourth-quarter sales. The company reported Q4 revenue of $17.56 billion and reaffirmed 2026 guidance. Some analysts remain cautious, with Acquirer’s Multiple valuing shares at $14–$15. Recent trial data showed positive results for Talzenna in prostate cancer and atirmociclib in breast cancer.
31 March 2026
··
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer shares fell 1.6% to $26.86 Thursday amid a broad U.S. market selloff as oil prices rose on Middle East tensions. The company faces pressure from declining COVID product sales and forecast 2026 profit below Wall Street estimates. China approved Pfizer’s GLP-1 weight-loss drug last week, while rival Eli Lilly announced a $3 billion China investment. Pfizer lost a legal bid in generic-drug litigation this week.
12 March 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares rose 2.7% to $27.22 Friday after the FDA granted Priority Review to its hemophilia drug HYMPAVZI, with a decision expected by mid-2026. Trading volume reached 30 million shares. The company also launched the TrumpRx discount program, offering cash discounts on over 30 drugs. The White House said TrumpRx.gov debuted Thursday with “most-favored nation” pricing on 40 branded drugs.
6 February 2026
···
Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer shares fell 1.1% to $26.49 in premarket trading after the TrumpRx discount drug portal launched Thursday, raising concerns over U.S. drug pricing. Pfizer said its TrumpRx program offers discounts of up to 85% on more than 30 medicines. The FDA granted Priority Review for expanding Hympavzi use in younger hemophilia patients, with a decision expected in the second quarter.
6 February 2026
··
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer shares rose 3.9% to $26.78 before holding steady after hours, following new data on its obesity drug PF-3944 and quarterly results. The company maintained its 2026 revenue and earnings outlook but warned of pricing pressures and upcoming patent expirations. Mid-stage trial data showed up to 12.3% weight loss at 28 weeks, with some patients dropping out due to side effects. Trading volume topped 80 million shares.
5 February 2026
·
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer shares rose 3.7% to $26.73 Wednesday after reporting Phase 2b trial results showing up to 12.3% placebo-adjusted weight loss at 28 weeks for its obesity drug PF’3944. The company reaffirmed its 2026 revenue and profit targets and said it will not pursue share buybacks. Pfizer reported Q4 adjusted EPS of 66 cents on $17.6 billion revenue. Full VESPER-3 results will be released June 6.
4 February 2026
··
Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer shares fell 3.4% to $25.77 in Wednesday’s premarket after Novo Nordisk warned of lower 2026 sales and price pressure in obesity drugs. Pfizer’s GLP-1 trial met its main goal, showing up to 12.3% mean weight loss at 28 weeks, but safety questions remain. The company reaffirmed 2026 guidance and reported $17.6 billion in Q4 revenue. Investors await more VESPER-3 data at the June 6 ADA meeting.
4 February 2026
··
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer shares fell 3.4% to $25.76 early Tuesday after quarterly results and new Phase 2b obesity drug data. The company reported adjusted Q4 earnings of 66 cents per share on $17.56 billion revenue, both above analyst estimates. Pfizer reaffirmed its 2026 outlook and does not plan share buybacks this year. COVID-19 product sales continued to decline sharply.
3 February 2026
··
1 2 3 … 10

Stock Market Today

  • Ecora Royalties Shares See Diverging Analyst Views as Price Targets Shift
    April 10, 2026, 9:37 PM EDT. Ecora Royalties (LSE: ECOR) is witnessing mixed analyst sentiment with price targets fluctuating. Canaccord raised its target by 30 GBp, signaling optimism on execution and valuation upside. Conversely, Peel Hunt downgraded the stock from Buy to Hold with a 154 GBp target, citing execution risks. Berenberg trimmed its price target by 10 GBp, reflecting caution despite not changing its rating. The updated valuation model nudged fair value slightly higher to £1.72 per share, adjusting revenue growth assumptions down from 40.88% to 12.22% and future price-to-earnings multiple from 37.79x to 33.27x. Ecora also announced a proposed final dividend of 1.40 cents per share for H2 2025, pending AGM approval. The share price narrative shows evolving risk perceptions and financial forecasts amid changing market conditions.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 9:47 PM EDT Ecora Royalties Shares See Diverging Analyst Views as Price Targets Shift April 10, 2026, 9:37 PM EDT. Ecora Royalties (LSE: ECOR) is witnessing mixed analyst sentiment with price targets fluctuating. Canaccord raised its target by 30 GBp, signaling optimism on execution and valuation upside. Conversely, Peel Hunt downgraded the stock from Buy to Hold with a 154 GBp target, citing execution risks. Berenberg trimmed its price target by 10 GBp, reflecting caution despite not changing its rating. The updated valuation model nudged fair value slightly
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Go toTop